Related Experiment Video
Updated: Mar 3, 2026

A Large Animal Model for Acute Kidney Injury by Temporary Bilateral Renal Artery Occlusion
Published on: February 2, 2021
Sodium-Glucose Cotransporter-2 Inhibitors and Acute Kidney Injury Risk: A Systematic Review and Meta-Analysis of
Yu-Cheng Chiang1, Dao-Fu Dai2, Yi-Wen Chiu3
1Department of Medical Education, Cathay General Hospital, Taiwan.
Rationale & Objective:
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) provide cardiovascular and renal benefits in individuals with or without type 2 diabetes. This systematic review and meta-analysis investigated the risks of acute kidney injury and other adverse events (AEs) associated with SGLT2is across diverse populations.
Study Design:
Systematic review and meta-analysis of randomized controlled trials (RCTs).
Setting & Study Populations:
Thirteen RCTs comprising 84,581 participants were included. The studies encompassed diverse populations, varying in diabetes status, presence of chronic kidney disease, and SGLT2i dosages.
Selection Criteria For Studies:
We included RCTs published through December 31, 2023, that evaluated the safety and efficacy of SGLT2is and reported renal and nonrenal adverse outcomes.
Data Extraction:
Two reviewers independently extracted data and resolved discrepancies by consensus, focusing on renal and nonrenal AEs and subgroup analyses.
Analytical Approach:
Random-effects meta-analysis was performed to estimate pooled relative risks or odds ratios with 95% confidence intervals (CIs). Heterogeneity was assessed using the I2 statistic.
Results:
SGLT2is were associated with a 20% reduction in the risk of acute kidney injury (relative risk, 0.80; 95% CI, 0.74-0.87), with low between-study heterogeneity, supporting a consistent renoprotective effect. Among patients with chronic kidney disease, the risk of renal composite outcomes was also significantly reduced (odds ratio, 0.70; 95% CI, 0.62-0.79). However, treatment was associated with increased risks of genital infections (P < 0.001), urinary tract infections (P = 0.03), diabetic ketoacidosis (P < 0.001), and hypovolemia (P = 0.008). No significant differences were observed for hypoglycemia (P = 0.08) or lower limb amputation (P = 0.07).
Limitations:
Variability in study design, definitions of AEs, and patient baseline characteristics may influence the findings.
Conclusions:
SGLT2is conferred substantial renoprotective benefits but increases the risk of certain nonrenal AEs. Tailored treatment and close monitoring are crucial to ensure safety and efficacy, especially in high-risk patients.
Insights
Sodium-glucose cotransporter-2 inhibitors (SGLT2is) significantly reduce acute kidney injury risk, offering renoprotective benefits. However, they are linked to increased risks of infections and diabetic ketoacidosis, necessitating careful patient monitoring.
Area of Science:
- Cardiovascular Medicine
- Nephrology
- Pharmacology
Background:
- Sodium-glucose cotransporter-2 inhibitors (SGLT2is) demonstrate cardiovascular and renal protective effects.
- Their safety profile, particularly regarding acute kidney injury (AKI) and other adverse events (AEs), requires comprehensive evaluation across diverse patient groups.
Purpose of the Study:
- To systematically review and meta-analyze randomized controlled trials (RCTs) evaluating the risks of AKI and other AEs associated with SGLT2is.
- To assess the efficacy and safety of SGLT2is in various populations, including those with and without type 2 diabetes and chronic kidney disease (CKD).
Main Methods:
- A systematic review and meta-analysis of 13 RCTs involving 84,581 participants, published up to December 31, 2023.
- Data extraction by two independent reviewers, focusing on renal and nonrenal AEs.
- Random-effects meta-analysis to calculate pooled relative risks and odds ratios with 95% confidence intervals (CIs).
Main Results:
- SGLT2is were associated with a 20% reduction in AKI risk (RR, 0.80; 95% CI, 0.74-0.87) with low heterogeneity.
- In patients with CKD, SGLT2is significantly reduced renal composite outcomes (OR, 0.70; 95% CI, 0.62-0.79).
- Increased risks were observed for genital infections, urinary tract infections, diabetic ketoacidosis, and hypovolemia, while no significant differences were found for hypoglycemia or lower limb amputation.
Conclusions:
- SGLT2is provide significant renoprotective benefits, reducing AKI and renal composite outcomes.
- The benefits must be weighed against increased risks of specific nonrenal AEs, including infections and diabetic ketoacidosis.
- Tailored treatment strategies and close monitoring are essential for optimizing SGLT2i safety and efficacy, particularly in high-risk individuals.
Related Concept Videos
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Acute Kidney Injury II: Pathophysiology
Acute Kidney Injury I: Introduction
Acute Kidney Injury V: Interprofessional Care
Acute Kidney Injury III: Clinical Manifestations
Acute Kidney Injury VI: Nursing Management
